

# 3

CANELLA 09/544,644

=&gt; d his

(FILE 'HOME' ENTERED AT 12:10:46 ON 10 APR 2002)

FILE 'REGISTRY' ENTERED AT 12:11:00 ON 10 APR 2002

L1 1327151 S PROTEIN/FS *over 1 million peptides/proteins in Reg file*

FILE 'HCAPLUS' ENTERED AT 12:20:18 ON 10 APR 2002

FILE 'REGISTRY' ENTERED AT 12:24:49 ON 10 APR 2002

L2 709857 S L1 AND SQL<101 *709,857 peptides w/ fewer than 101 residues*

FILE 'HCAPLUS' ENTERED AT 12:25:13 ON 10 APR 2002

FILE 'REGISTRY' ENTERED AT 12:25:31 ON 10 APR 2002

L3 262309 S L2 AND SQL&gt;20

L4 447548 S L2 NOT L3

L5 258651 S L4 AND SQL&lt;10

L6 188897 S L4 NOT L5

*} breaking down L2 into smaller  
answer sets for cross over to HCAPL*

FILE 'HCAPLUS' ENTERED AT 12:33:44 ON 10 APR 2002

L7 66032 S L3 *66,032 citations for L3 peptides (# residues 21 or more)*L8 121087 S L5 *121,087 " " L5 " (# residues is 9 or fewer)*L9 81097 S L6 *81,097 " " L6 " (# residues is between 10-*L10 864 S L7-L9(L) (HYDROPHOB? OR LIPOPHIL?) *linking cpds in L7-9 wi*L11 15 S L10(L) CONJUGAT? *applicant's work claimed propriety*

L12 1 S 2000:725483/AN

L13 14 S L11 NOT L12

L14 9 S L13 AND PATENT/DT

L15 8 S L14 AND PRD<19990704 *8 patents w/ priority date < 7/4/1999*L16 5 S L13 NOT L14 *5 literature cites*

FILE 'REGISTRY' ENTERED AT 12:53:34 ON 10 APR 2002

L17 0 S L2 AND (HYDROPHOB? OR LIPOPHIL?)/NTE

=&gt; d ibib abs hitstr 1

L16 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:371221 HCAPLUS

DOCUMENT NUMBER: 131:181722

TITLE: 99m-technetium-labelled peptide-HYNIC conjugates:  
Effects of lipophilicity and stability on  
biodistribution

AUTHOR(S): Decristoforo, Clemens; Mather, Stephen J.

CORPORATE SOURCE: Nuclear Medicine Research Laboratory, St.  
Bartholomew's Hospital, London, UKSOURCE: Nucl. Med. Biol. (1999), 26(4), 389-396  
CODEN: NMBIEO; ISSN: 0969-8051

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The aim of this study was to explore the effects of lipophilicity and stability on the biodistribution of 99mTc labeled peptides through the use of different co-ligands. 6-Hydrazinopyridine-3-carboxylic acid (HYNIC) was coupled to the somatostatin analog RC160 and radiolabeled using a range of ethylenediaminediacetic acid (EDDA) and EDTA derivs. as well as tricine and pyridine/tricine as co-ligands. After labeling with technetium-99m, chromatog., stability, protein-binding, and rat biodistribution studies were performed. For most co-ligands, biodistribution correlated well with in vitro properties. Lipophilic substitution on EDDA resulted in higher protein binding, increased liver uptake, and intestinal excretion. Stabilization of tricine with pyridines reduced blood levels and lowered liver uptake. EDTA derivs. showed high instability in vitro and in vivo.

IT 103222-11-3DP, RC160, 99mTc-labeled HYNIC conjugate

RL: BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(effects of **lipophilicity** and stability on biodistribution of 99mTc-labeled peptide-HYNIC conjugates)

RN 103222-11-3 HCAPLUS

CN L-Tryptophanamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2.fwdarw.7)-disulfide (9CI) (CA INDEX NAME)



CANELLA 09/544,644

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 2

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:207844 HCAPLUS

DOCUMENT NUMBER: 106:207844

TITLE: A receptor-binding region in human  
choriogonadotropin/lutropin .beta. subunitAUTHOR(S): Keutmann, Henry T.; Charlesworth, M. Cristine; Mason,  
Kathleen A.; Ostrea, Teofila; Johnson, Leslie; Ryan,  
Robert J.CORPORATE SOURCE: Endocr. Unit, Massachusetts Gen. Hosp., Boston, MA,  
02114, USASOURCE: Proc. Natl. Acad. Sci. U. S. A. (1987), 84(7), 2038-42  
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of peptides representing the intercysteine loop sequence (residues 38-57) in human choriogonadotropin (hCG) and lutropin (hLH) .beta. subunits were prepd. The peptides were characterized chem. and tested for bioactivity by binding to rat ovarian membrane receptor and stimulation of Leydig cell testosterone [58-22-0] prodn. The hCG.beta.-(38-57) [108324-52-3] and hLH.beta.-(38-57) [108324-53-4] peptides inhibited binding of 125I-labeled hCG half-maximally at 1.51 .times. 10<sup>-4</sup> and 2.03 .times. 10<sup>-5</sup>M, resp., whereas other peptide hormones and fragments from elsewhere in the .beta. subunit were inactive. Both peptides stimulated testosterone prodn., with half-max. responses at 3.55 .times. 10<sup>-5</sup>M (hCG) and 2.18 .times. 10<sup>-5</sup>M (hLH). By radioimmunoassay with an antibody to thyroglobulin-**conjugated** hCG.beta.-(38-57) peptide, native hCG, and .beta. subunit were highly reactive, as were the reduced and carboxymethylated subunit and peptide. Helical-wheel projection predicted an amphipathic region in the N-terminal portion of the 38-57 sequence, and circular dichroic measurements showed an increase in ordered structure, esp. .alpha.-helix, when the 38-57 peptides were transferred from an aq. to a more **lipophilic** (90% trifluoroethanol) environment. Apparently, the 38-57 region of .beta. subunit is exposed on the surface and constitutes a component in the receptor-binding domain for hCG and hLH. A region of amphipathic-helical structure in the 38-57 sequence may promote hormone-receptor interactions in a manner proposed for several other peptide hormones.

=> d ind 2

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS  
 CC 2-2 (Mammalian Hormones)  
 ST gonadotropin receptor structure activity; chorionic gonadotropin receptor structure activity; LH receptor structure activity  
 IT Ovary, metabolism  
     (chorionic gonadotropin and LH .beta.-subunit fragments binding by, from human, structure in relation to)  
 IT Receptors  
     RL: BIOL (Biological study)  
     (chorionic gonadotropin and LH .beta.-subunit fragments binding of, from human, structure in relation to)  
 IT Cell membrane  
     (gonadotropin receptors of, of ovary, chorionic gonadotropin and LH fragments from human binding of)  
 IT Conformation and Conformers  
     (of chorionic gonadotropin and LH .beta.-subunit fragments, from human)  
 IT Testis, metabolism  
     (Leydig cell, testosterone formation by, chorionic gonadotropin and LH .beta.-subunits from human stimulation of)  
 IT Molecular structure-biological activity relationship  
     (receptor-binding, of chorionic gonadotropin and LH .beta.-subunits from human)  
 IT 58-22-0, Testosterone  
     RL: FORM (Formation, nonpreparative)  
     (formation of, by testis Leydig cell, human chorionic gonadotropin and LH .beta.-subunit fragments effect on)  
 IT 83073-94-3 83578-98-7 108303-20-4 108303-21-5  
     RL: PROC (Process)  
     (gonadotropin receptor binding of, structure in relation to)  
 IT 108303-18-0P 108303-19-1P 108324-52-3P 108324-53-4P 108348-45-4P  
     RL: SPN (Synthetic preparation); PREP (Preparation)  
     (prepn. and gonadotropin receptor binding of, structure in relation to)

=> d ibib abs hitstr 3

L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1986:584091 HCAPLUS

DOCUMENT NUMBER: 105:184091

TITLE: Chemical synthesis and immunological properties of a cyclic eicosapeptide (Gly88,90) 82-101 of the beta subunit of human chorionic gonadotropin

AUTHOR(S): Iyer, K. S. N.; Sahal, D.; Talwar, G. P.

CORPORATE SOURCE: Natl. Inst. Immunol., New Delhi, India

SOURCE: Int. J. Pept. Protein Res. (1986), 27(6), 604-12

CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The eicosapeptide cyclic[Gly88,90]82-101 human chorionic gonadotropin-.beta. (I) [105028-22-6] was prepd. by fragment condensation of the nonapeptide (Gly88,90)82-90 with the undecapeptide 91-101 followed by I oxidn. to form the disulfide group and examd. for immunol. properties. Anti-I antibodies were elicited in rabbits by immunization with a **conjugate** of I with tetanus toxoid. These antibodies showed a similar recognition pattern for the eicosapeptide I and the undecapeptide 91-101. The entire spectrum of antibodies was directed against hydrophilic undecapeptide 91-101, since the **hydrophobic** nonapeptide (Gly88,90)82-90 failed to show recognition. I antibodies failed to recognize human chorionic gonadotropin or its .beta.-subunit (hCG-.beta.) suggesting that the conformational epitopes of hCG-.beta. in the region 82-101 may not be accessible to antibodies.

=&gt; d ind 3

L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS  
 CC 2-1 (Mammalian Hormones)  
 Section cross-reference(s): 15, 34  
 ST chorionic gonadotropin cyclic deriv prepn immunol; antibody chorionic  
 gonadotropin cyclic deriv  
 IT Antibodies  
 RL: PROC (Process)  
 (to chorionic gonadotropin .beta.-subunit cyclic deriv.,  
 characterization of)  
 IT Toxoids  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (tetanus, reaction products with chorionic gonadotropin .beta.-subunit  
 cyclic deriv., prepn. of)  
 IT 105047-72-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and cyclization of)  
 IT 105028-24-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deblocking and reaction of, with protected alanine)  
 IT 105047-69-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection and reaction of, with protected alanine)  
 IT 65985-39-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection and reaction of, with protected glycine)  
 IT 75410-01-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection and reaction of, with protected serine)  
 IT 105047-70-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection and reaction of, with protected tyrosine)  
 IT 105028-25-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection and reaction of, with protected valine)  
 IT 105047-71-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deprotection of)  
 IT 105028-22-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and immunol. properties of)  
 IT 105028-23-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, with protected leucine)  
 IT 105028-27-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, with protected nonapeptide)  
 IT 105047-68-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, with protected serine)  
 IT 105028-26-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction of, with protected undecapeptide)  
 IT 105028-22-6DP, reaction products with tetanus toxoid  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 IT 15387-45-8  
 RL: RCT (Reactant)

(reaction of, with glycine benzyl ester toluenesulfonate)  
 IT 4530-20-5  
 RL: RCT (Reactant)  
 (reaction of, with protected dipeptide)  
 IT 1738-76-7  
 RL: RCT (Reactant)  
 (reaction of, with protected glutamine)  
 IT 13734-41-3  
 RL: RCT (Reactant)  
 (reaction of, with protected hexapeptide)  
 IT 2130-96-3  
 RL: RCT (Reactant)  
 (reaction of, with protected octapeptide)  
 IT 13139-15-6  
 RL: RCT (Reactant)  
 (reaction of, with protected tetrapeptide)  
 IT 23680-31-1  
 RL: RCT (Reactant)  
 (reaction of, with protected tripeptide)



=&gt; d ibib abs hitstr 4

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1985:215558 HCAPLUS

DOCUMENT NUMBER: 102:215558

TITLE: Protein-peptide conjugation by a two-phase reaction

AUTHOR(S): Myers, D. A.; Murdoch, W. J.; Villemez, C. L.

CORPORATE SOURCE: Dep. Anim. Sci., Univ. Wyoming, Laramie, WY, 82071, USA

SOURCE: Biochem. J. (1985), 227(1), 343

CODEN: BIJOAK; ISSN: 0306-3275

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To **conjugate** (D-Lys6,de-Gly10)-LH-RH ethylamide (I) [59131-98-5] with proteins, I was reacted with N-succinimidyl 3-(pyridyldithio)propionate, the pyridyl disulfide propionate-derivatized I quant. pptd., and then redissolved on exposure to aq. solns. of mercaptoethanol. The derivatized I was dispersed in aq. soln. by sonic oscillation. A 4-fold molar excess of derivatized I was **conjugated** with diphtheria toxins A-chains after a 60-min incubation at room temp. The extent of **conjugation** was measured by absorbance at 343 mμ (pyridine-2-thione absorbance). Since removal of the pyridyl residue allowed derivatized I to redissolve, the increased **hydrophobicity** of pyridyl disulfide propionate I is apparently the sole cause of the pptn. This 2-phase reaction should be useful in the **conjugation** of other small peptides with proteins.

=> d ind 4

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS  
CC 2-5 (Mammalian Hormones)  
ST LHRH conjugation toxin; peptide conjugation protein  
IT Proteins  
RL: RCT (Reactant)  
(coupling of, with peptides, 2-phase reaction in)  
IT Peptides, reactions  
RL: RCT (Reactant)  
(coupling of, with protein, 2-phase reaction for)  
IT Toxins  
RL: BIOL (Biological study)  
(diphtheria, A-chain, LH-RH analog coupling with, 2-phase reaction for)  
IT 59131-98-5  
RL: RCT (Reactant)  
(coupling of, with protein, 2-phase reaction for)

=> d ibib abs hitstr 5

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1980:507874 HCAPLUS

DOCUMENT NUMBER: 93:107874

TITLE: Structure of tremmerogen A-10, a peptidal hormone inducing conjugation tube formation in Tremella mesenterica, and biological activity of synthetic analogs

AUTHOR(S): Sakagami, Youji; Isogai, Akira; Suzuki, Akinori; Kitada, Chieko; Fujino, Masahiko

CORPORATE SOURCE: Dep. Agric. Chem., Univ. Tokyo, Tokyo, 113, Japan

SOURCE: Pept. Chem. (1980), Volume Date 1979, 17th, 1-6  
CODEN: PECHDP

DOCUMENT TYPE: Journal

LANGUAGE: English

AB When 16 derivs. of tremmerogen A-10 [67417-46-3], a peptide hormone inducing **conjugation** tube formation in T. mesenterica, were tested, a blocked C terminus was shown to be essential for biol. activity. Neither SH-dodecapeptides nor S-farnesyl-peptides truncated at N-terminus showed detectable biol. activity, whereas a **lipophilic** moiety on dodecapeptides gave a biol. active analog. Of synthetic analogs with different prenyl units tested, analogs which had 5 and 6 prenyl units were more active than the natural hormone. The analogs with enhanced potency may be useful tools for studies on the mol. mechanism of sexual mating of yeast.

=> d ind 5

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS

CC 3-2 (Biochemical Interactions)

Section cross-reference(s): 2, 6

ST tremmerogen analog Tremella reprodn

IT Tremella mesenterica

(conjugation tube formation in, tremmerogen analogs effect on)

IT Reproduction

(in Tremella mesenterica, tremmerogen hormone analogs effect on)

IT 67417-46-3 69150-54-5 69150-56-7 74635-04-4 74635-05-5

74635-06-6 74635-07-7 74635-08-8 74635-09-9 74635-10-2

74635-11-3 74635-12-4 74635-13-5 74635-14-6 74635-15-7

74635-16-8 74708-39-7

RL: PRP (Properties)

(conjugation tube formation response to, in Tremella mesenterica)

=&gt; d ibib abs hitstr 1

L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:721487 HCAPLUS

DOCUMENT NUMBER: 135:273221

TITLE: Preparation of lipophilic human glucagon-like peptide-1 derivatives with protracted action profiles

INVENTOR(S): Knudsen, Liselotte; Huusfeldt, Per Olaf; Nielsen, Per Franklin; Kaarsholm, Niels C.; Olsen, Helle Birk; Bjorn, Soren Erik; Pedersen, Freddy Zimmerdahl; Madsen, Kjeld

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: U.S., 136 pp., Cont.-in-part of U.S. Ser. No. 38,432, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6268343	B1	20010731	US 1999-258750	19990226 <--
WO 9808871	A1	19980305	WO 1997-DK340	19970822 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2001011095	A2	20010116	JP 2000-152778	19970822 <--
ZA 9901571	A	19990902	ZA 1999-1571	19990226 <--
US 2001011071	A1	20010802	US 1999-398111	19990916 <--
US 2002025933	A1	20020228	US 2001-908534	20010718 <--
PRIORITY APPLN. INFO.:				
			DK 1996-931	A 19960830 <--
			DK 1996-1259	A 19961108 <--
			DK 1996-1470	A 19961220 <--
			US 1997-36255P	P 19970124 <--
			US 1997-36226P	P 19970125 <--
			WO 1997-DK340	A2 19970822 <--
			US 1997-918810	B2 19970826 <--
			DK 1998-263	A 19980227 <--
			DK 1998-264	A 19980227 <--
			DK 1998-268	A 19980227 <--
			DK 1998-272	A 19980227 <--
			DK 1998-274	A 19980227 <--
			US 1998-38432	B2 19980311 <--
			DK 1998-508	A 19980408 <--
			DK 1998-509	A 19980408 <--
			US 1998-82478P	P 19980421 <--
			US 1998-82480P	P 19980421 <--
			US 1998-84357P	P 19980421 <--
			US 1998-82802P	P 19980423 <--
			US 1997-35905P	P 19970124 <--
			JP 1998-511183	A3 19970822 <--
			US 1997-922200	B2 19970902 <--
			DK 1998-271	A 19980227 <--
			US 1998-78422P	P 19980318 <--

US 1998-82479P P 19980421 <--  
 US 1998-85789P P 19980518 <--  
 US 1999-258187 B1 19990225 <--  
 US 1999-258750 A2 19990226 <--  
 US 1999-265141 A2 19990308 <--

OTHER SOURCE(S): MARPAT 135:273221

AB The present invention relates to human glucagon-like peptide-1 (GLP-1) derivs. having a lipophilic substituent, compns. contg. these derivs., and to methods for their prepn. A claimed compd. is His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly. Thus, coupling of GLP-1(7-37)-OH with Me(CH<sub>2</sub>)<sub>12</sub>CO-Glu(OSu)-OCMe<sub>3</sub> (Su = succinimidyl) (prepn. given), followed by deesterification with CF<sub>3</sub>CO<sub>2</sub>H and chromatog. purifn. gave 8% bis-adduct Lys[Me(CH<sub>2</sub>)<sub>12</sub>CO-.gamma.-Glu]26,34-GLP-1(7-37)-OH. Several prepd. lipophilic GLP-1 analogs were tested for protracted plasma concn. in pigs and were found to be much more persistent than GLP-1(7-37). In addn., the time of peak plasma concn. was found to vary within wide limits depending on the particular lipophilic GLP-1 deriv. selected. The efficacy of several prepd. derivs. was tested by stimulation of cAMP in a cell line expressing cloned human GLP-1 receptor.

IT 240133-31-7P 240133-32-8P 240133-33-9P  
 240480-97-1P 240480-98-2P 240480-99-3P  
 240481-01-0P 240481-02-1P 240481-03-2P  
 240481-04-3P 240481-05-4P 240481-06-5P  
 240481-07-6P 240481-08-7P 240481-09-8P  
 240481-10-1P 240481-11-2P 240481-12-3P  
 240481-13-4P 240481-22-5P 240481-24-7P  
 240481-25-8P 240481-27-0P 240481-32-7P  
 240481-33-8P 240481-35-0P 240482-41-1P  
 240482-42-2P 240482-43-3P 240482-44-4P  
 240482-45-5P 240483-55-0P 240483-71-0P  
 240497-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(glucagon-like peptide **conjugates**; prepn. of  
**lipophilic** human glucagon-like peptide-1 derivs. with  
 protracted action profiles)

RN 240133-31-7 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-(1-oxododecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B








PAGE 1-E



PAGE 2-B




PAGE 2-C




RN 240133-32-8 HCAPLUS  
 CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-(1-oxooctyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B




PAGE 2-C




RN 240133-33-9 HCAPLUS  
 CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(1-oxododecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B



PAGE 2-C



RN 240480-97-1 HCAPLUS  
 CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240480-98-2 HCAPLUS  
 CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-

L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240480-99-3 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-[(3.alpha.,5.beta.)-3-hydroxy-24-oxocholan-24-yl]-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-01-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-02-1 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-03-2 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-04-3 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-05-4 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)



\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-06-5 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxooctyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-07-6 HCAPLUS

CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-08-7 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-09-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-(1-oxohexadecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-10-1 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-11-2 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-12-3 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-tyrosyl-L-leucyl-L-.alpha.-

glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-13-4 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-22-5 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxotetradecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-24-7 HCAPLUS

CN Glycine, L-histidyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-25-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxododecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-27-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-.beta.-alanyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-32-7 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-.alpha.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-33-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[[1-(1-oxohexadecyl)-4-piperidinyl]carbonyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-35-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-(1-oxodecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-41-1 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-42-2 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-.beta.-alanyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-43-3 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxo-2-propenyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-44-4 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxotetradecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-45-5 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-

aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-  
glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-  
oxooctadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-  
isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-  
(9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240483-55-0 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-  
glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-  
aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-  
glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-  
.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-  
alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA  
INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240483-71-0 HCAPLUS

CN Glycine, N-(1H-imidazol-4-ylacetyl)-L-alanyl-L-.alpha.-glutamylglycyl-L-  
threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-  
seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-  
alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-  
.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-  
L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*



RN 240497-59-0 HCAPLUS

CN Glycine, L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-  
seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-  
.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(1-  
oxotetradecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-  
phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-  
arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-D



PAGE 2-B



PAGE 2-C



IT 176435-11-3 240133-43-1 240133-44-2  
 240133-45-3 240133-46-4 240133-47-5  
 240133-49-7 240133-50-0 240133-51-1  
 240481-37-2 240481-39-4


RL: RCT (Reactant); RACT (Reactant or reagent)  
 (glucagon-like peptide **conjugates**; prepn. of  
**lipophilic** human glucagon-like peptide-1 derivs. with  
 protracted action profiles)

RN 176435-11-3 HCAPLUS


CN 8-37-Glucagon-like peptide I (human), N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-  
 26-L-arginine- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B









PAGE 1-E



PAGE 2-B




PAGE 2-C




RN 240133-43-1 HCAPLUS  
 CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D






RN 240133-44-2 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 1-C





PAGE 2-B



PAGE 2-C




RN 240133-45-3 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-lysyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C







PAGE 1-D



PAGE 1-E



PAGE 2-C




```

RN      240133-46-4  HCAPLUS
CN      Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-
        phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-lysyl-
        L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-
        L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
        tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI)  (CA INDEX
        NAME)


```

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D



PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-47-5 HCAPLUS


CN Glycine, L-histidyl-L-lysyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D



PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-49-7 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A







PAGE 1-B




PAGE 1-C




PAGE 1-D




PAGE 1-E



PAGE 2-B



PAGE 2-C






RN 240133-50-0 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxo-2-propenyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







PAGE 1-D




PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-51-1 HCAPLUS


CN Glycine, N-(1H-imidazol-4-ylacetyl)-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D



PAGE 1-E




PAGE 2-B





PAGE 2-C



RN 240481-37-2 HCAPLUS  
 CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-(9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-39-4 HCAPLUS  
 CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-(9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 2

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:651565 HCAPLUS

DOCUMENT NUMBER: 135:207894

TITLE: Adhesion of cells and biomolecules to hydrophobic surfaces using conjugated end-group activated polymers  
 INVENTOR(S): Caldwell, Karin D.; Tresco, Patrick A.; Neff, Jennifer  
 PATENT ASSIGNEE(S): University of Utah Research Foundation, USA  
 SOURCE: U.S., 23 pp., Cont.-in-part of U.S. 5,728,588.  
 CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6284503	B1	20010904	US 1997-784203	19970115 <--
US 5516703	A	19960514	US 1993-110169	19930820
US 5728588	A	19980317	US 1995-399913	19950307 <--
WO 9831734	A1	19980723	WO 1998-US337	19980115 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9860182	A1	19980807	AU 1998-60182	19980115 <--
AU 740877	B2	20011115		
EP 1002066	A1	20000524	EP 1998-903402	19980115 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2002019037	A1	20020214	US 2001-946079	20010904 <--
PRIORITY APPLN. INFO.:				
			US 1993-110169	A3 19930820 <--
			US 1995-399913	A2 19950307 <--
			US 1997-784203	A 19970115 <--
			WO 1998-US337	W 19980115 <--
AB	The present invention is directed to a compn. and method for regulating the adhesion of cells and biomols. to hydrophobic surfaces and hydrophobic coated surfaces. The compn. is a biomol. conjugated end-group activated polymer (FGAP). Thus, the end groups of a PEO- and PPO-contg. block copolymer (e.g., Plutonic F108) is coated on a hydrophobic surface, end-group modified/thiolated by reaction with 4-nitrophenylchloroformate followed by 2-(2-pyridyldithio)ethylamine, and conjugated with a thiol-contg. biopolymer. The biomol. conjugated EGAP can be put to numerous uses including cell adhesion, cell growth, cell sorting, and other biol. assays.			
IT	<b>91037-65-9D, conjugated 140457-22-3D, conjugated</b>			
	RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)			
	(adhesion of cells and biomols. to <b>hydrophobic</b> surfaces using <b>conjugated</b> end-group activated polymers)			
RN	91037-65-9 HCAPLUS			
CN	L-Serine, L-arginylglycyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)			


Absolute stereochemistry. Rotation (-).



RN 140457-22-3 HCAPLUS

CN L-Tyrosine, glycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

55

THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 3

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:566665 HCAPLUS

DOCUMENT NUMBER: 135:122756

TITLE: Preparation of lipophilic human glucagon-like peptide-1 derivatives with protracted action profiles  
 INVENTOR(S): Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf; Nielsen, Per Franklin; Kaarsholm, Niels C.; Olsen, Helle Birk; Bjorn, Soren Erik; Pedersen, Freddy Zimmerdahl; Madsen, Kjeld

PATENT ASSIGNEE(S): Den.

SOURCE: U.S. Pat. Appl. Publ., 133 pp., Cont.-in-part of U.S. Ser. No. 265,141.  
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

*Same inv. as  
 #1 in this  
 set*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001011071	A1	20010802	US 1999-398111	19990916 <--
WO 9808871	A1	19980305	WO 1997-DK340	19970822 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
JP 2001011095	A2	20010116	JP 2000-152778	19970822 <--
US 6268343	B1	20010731	US 1999-258750	19990226 <--
US 2002025933	A1	20020228	US 2001-908534	20010718 <--
PRIORITY APPLN. INFO.:			DK 1996-931	A 19960830 <--
			DK 1996-1259	A 19961108 <--
			DK 1996-1470	A 19961220 <--
			US 1997-36255P	P 19970124 <--
			US 1997-36226P	P 19970125 <--
			US 1998-84357P	P 19970822 <--
			WO 1997-DK340	W 19970822 <--
			US 1997-918810	B2 19970826 <--
			DK 1998-263	A 19980227 <--
			DK 1998-264	A 19980227 <--
			DK 1998-268	A 19980227 <--
			US 1998-38432	B2 19980311 <--
			US 1998-78422P	P 19980318 <--
			US 1998-82478P	P 19980421 <--
			US 1998-82479P	P 19980421 <--
			US 1998-82480P	P 19980421 <--
			US 1998-82802P	P 19980423 <--
			US 1999-258750	A2 19990226 <--
			US 1999-265141	A2 19990308 <--
			US 1997-35905P	P 19970124 <--
			JP 1998-511183	A3 19970822 <--
			US 1997-922200	B2 19970902 <--
			DK 1998-271	A 19980227 <--
			DK 1998-272	A 19980227 <--

DK 1998-274	A	19980227 <--
DK 1998-508	A	19980408 <--
DK 1998-509	A	19980408 <--
US 1998-85789P	P	19980518 <--
US 1999-258187	B1	19990225 <--

OTHER SOURCE(S): MARPAT 135:122756

AB The present invention relates to pharmaceutical compns. comprising lipophilic human glucagon-like peptide-1 (GLP-1) derivs. having a lipophilic substituent and a surfactant. Thus, coupling of GLP-1(7-37)-OH with Me(CH<sub>2</sub>)<sub>12</sub>CO-Glu(OSu)-OCMe<sub>3</sub> (Su = succinimidyl) (prepn. given), followed by deesterification with CF<sub>3</sub>CO<sub>2</sub>H and chromatog. purifn. gave 8% bis-adduct Lys[Me(CH<sub>2</sub>)<sub>12</sub>CO-.gamma.-Glu]<sub>26,34</sub>-GLP-1(7-37)-OH. Several prepd. lipophilic GLP-1 analogs were tested for protracted plasma concn. in pigs and were found to be much more persistent than GLP-1(7-37). In addn., the time of peak plasma concn. was found to vary within wide limits depending on the particular lipophilic GLP-1 deriv. selected. The efficacy of several prepd. derivs. was tested by stimulation of cAMP in a cell line expressing cloned human GLP-1 receptor.

IT 240133-31-7P 240133-32-8P 240133-33-9P  
 240480-97-1P 240480-98-2P 240480-99-3P  
 240481-01-0P 240481-02-1P 240481-03-2P  
 240481-04-3P 240481-05-4P 240481-06-5P  
 240481-07-6P 240481-08-7P 240481-09-8P  
 240481-10-1P 240481-11-2P 240481-12-3P  
 240481-13-4P 240481-22-5P 240481-24-7P  
 240481-25-8P 240481-27-0P 240481-32-7P  
 240481-33-8P 240481-35-0P 240482-41-1P  
 240482-42-2P 240482-43-3P 240482-44-4P  
 240482-45-5P 240483-55-0P 240483-71-0P  
 240497-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(glucagon-like peptide **conjugates**; prepn. of  
**lipophilic** human glucagon-like peptide-1 derivs. with  
 protracted action profiles)

RN 240133-31-7 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N<sub>6</sub>-(1-oxodecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




4.5


PAGE 1-C




PAGE 1-D



PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-32-8 HCAPLUS  
 CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(1-oxooctyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-33-9 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(1-oxododecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B



PAGE 2-C



RN 240480-97-1 HCAPLUS

CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240480-98-2 HCAPLUS

CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-

L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240480-99-3 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-[(3.alpha.,5.beta.)-3-hydroxy-24-oxocholan-24-yl]-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-01-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-02-1 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-03-2 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-04-3 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-05-4 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-06-5 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxooctyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-07-6 HCAPLUS

CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-08-7 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(1-oxooctadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-09-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-(1-oxohexadecyl)-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-10-1 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-11-2 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-12-3 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-tyrosyl-L-leucyl-L-.alpha.-



glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-13-4 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-22-5 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-[N-(1-oxotetradecyl)-L-.gamma.-glutamyl]-L-lysylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-24-7 HCAPLUS

CN Glycine, L-histidyl-N6-[N-(1-oxohexadecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-25-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxododecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-27-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-.beta.-alanyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-32-7 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-.alpha.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-33-8 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[(1-(1-oxohexadecyl)-4-piperidinyl]carbonyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-35-0 HCAPLUS

CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-(1-oxodecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-41-1 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-42-2 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-.beta.-alanyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-43-3 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxo-2-propenyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-44-4 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxotetradecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240482-45-5 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-

aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-  
glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[1-oxo-4-[(1-  
oxooctadecyl)amino]butyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-  
isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-  
(9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240483-55-0 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-  
glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-  
aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-  
glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(1-oxohexadecyl)-L-  
.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-  
alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA  
INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240483-71-0 HCAPLUS

CN Glycine, N-(1H-imidazol-4-ylacetyl)-L-alanyl-L-.alpha.-glutamylglycyl-L-  
threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-  
seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-  
alanyl-L-alanyl-N6-[1-oxo-4-[(1-oxohexadecyl)amino]butyl]-L-lysyl-L-  
.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-  
L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*



RN 240497-59-0 HCAPLUS

CN Glycine, L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-  
seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-  
.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(1-  
oxotetradecyl)-L-.gamma.-glutamyl]-L-lysyl-L-.alpha.-glutamyl-L-  
phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-  
arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-D



PAGE 2-B




PAGE 2-C




IT 176435-11-3 204521-81-3 240133-43-1  
 240133-44-2 240133-45-3 240133-46-4  
 240133-47-5 240133-49-7 240133-50-0  
 240133-51-1 240481-37-2 240481-39-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (glucagon-like peptide **conjugates**; prepn. of  
 lipophilic human glucagon-like peptide-1 derivs. with  
 protracted action profiles)  
 RN 176435-11-3 HCAPLUS  
 CN 8-37-Glucagon-like peptide I (human), N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-  
 26-L-arginine- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 204521-81-3 HCAPLUS  
 CN 7-36-Glucagon-like peptide 1 (Octodon degus), 26-L-arginine-36a-glycine-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 1-A




PAGE 1-B






PAGE 1-E



PAGE 2-B




PAGE 2-C




RN 240133-43-1 HCAPLUS  
 CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D






RN 240133-44-2 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-lysyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 1-C








PAGE 2-B



PAGE 2-C




RN 240133-45-3 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-lysyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D



PAGE 1-E








RN 240133-46-4 HCAPLUS


CN Glycine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 1-D




PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-47-5 HCAPLUS


CN Glycine, L-histidyl-L-lysyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B




PAGE 1-C







PAGE 2-B



PAGE 2-C






RN 240133-49-7 HCAPLUS




CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxopropyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A







PAGE 2-C






RN 240133-50-0 HCAPLUS

CN Glycine, N-[3-(1H-imidazol-4-yl)-1-oxo-2-propenyl]-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







PAGE 1-D




PAGE 1-E



PAGE 2-B



PAGE 2-C




RN 240133-51-1 HCAPLUS



CN Glycine, N-(1H-imidazol-4-ylacetyl)-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A









PAGE 1-D



PAGE 1-E



PAGE 2-B



&lt;-----User Break-----&gt;

RN 240481-37-2 HCAPLUS

CN L-Lysine, L-histidylglycyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-(9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 240481-39-4 HCAPLUS

CN L-Lysine, L-histidyl-L-alanyl-L-.alpha.-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-.alpha.-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-.alpha.-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-arginyl-L-.alpha.-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-L-.alpha.-glutamyl-(9CI) (CA INDEX NAME)u

=&gt;

=&gt; d ibib abs hitstr 4

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:131193 HCAPLUS

DOCUMENT NUMBER: 134:183490

TITLE: Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin

INVENTOR(S): Ekwuribe, Nnochiri Nkem; Ramaswamy, Muthukumar; Radhakrishnan, Balasingam; Allaudeen, Hameedsulthan S.

PATENT ASSIGNEE(S): Protein Delivery, Inc., USA

SOURCE: U.S., 32 pp., Cont.-in-part of U. S. 5,681,811.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191105	B1	20010220	US 1997-958383	19971027 <--
US 5359030	A	19941025	US 1993-59701	19930510
US 5438040	A	19950801	US 1994-276890	19940719 <--
US 5681811	A	19971028	US 1995-509422	19950731 <--
PRIORITY APPLN. INFO.:			US 1993-59701	A3 19930510 <--
			US 1994-276890	A2 19940719 <--
			US 1995-509422	A2 19950731 <--

AB A therapeutic formulation comprising a microemulsion of a therapeutic agent in free and/or conjugate coupled form, wherein the microemulsion comprises a water-in-oil (w/o) microemulsion including a lipophilic phase and a hydrophilic phase, and has a hydrophilic and lipophilic balance (HLB) value between 3 and 7 is described. The therapeutic agent is selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminase, adenosine deaminase, RNase, trypsin, chymotrypsin, papain, Ara-A (Arabinofuranosyladenine), acylguanosine, nordeoxyguanosine, azidothymidine, dideoxyadenosine, dideoxycytidine, dideoxyinosine, floxuridine, 6-mercaptapurine, doxorubicin, daunorubicin, or I-darubicin, erythromycin, vancomycin, oleandomycin, ampicillin, quinidine and heparin. In a particular aspect, the invention comprises an insulin compn. suitable for parenteral as well as non-parenteral administration, preferably oral or parenteral administration, comprising insulin covalently coupled with a polymer including (i) a linear polyalkylene glycol moiety and (ii) a lipophilic moiety, wherein the insulin, the linear polyalkylene glycol moiety and the lipophilic moiety are conformationally arranged in relation to one another such that the insulin in the compn. has an enhanced in vivo resistance to enzymic degradn., relative to insulin alone. The microemulsion compns. of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications. For example, a microemulsion formulation was prepd. contg. Capmul MCM 53.0, Centrophase 31 5.7, propylene glycol 19.9, Tween 80 1.4, hexyl insulin in NaP buffer 15 mg/mL, and NaP buffer up to 100%, resp. Also, prepn. of hexyl insulin conjugates with Me (ethylene glycol)7-O-hexanoic acid was carried out.

IT 11070-73-8, Bovine insulin

RL: RCT (Reactant); RACT (Reactant or reagent)

(hydrophilic and **lipophilic** balanced microemulsions of free and/or **conjugated** drugs such as insulin)

RN 11070-73-8 HCAPLUS

CN Insulin (cattle) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 11070-73-8DP, Bovine insulin, **conjugates**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrophilic and **lipophilic** balanced microemulsions of free and/or **conjugated** drugs such as insulin)

RN 11070-73-8 HCAPLUS

CN Insulin (cattle) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 1404-90-6, Vancomycin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophilic and **lipophilic** balanced microemulsions of free and/or **conjugated** drugs such as insulin)

RN 1404-90-6 HCAPLUS


CN Vancomycin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Bu-i



REFERENCE COUNT:

54

THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 5

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:911065 HCAPLUS

DOCUMENT NUMBER: 134:76386

TITLE: Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same

INVENTOR(S): Ekwuribe, Nnochiri; Ramaswamy, Muthukumar; Rajagopalan, Jayanthi

PATENT ASSIGNEE(S): Protein Delivery, Inc., USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078302	A1	20001228	WO 2000-US16879	20000619 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309633	B1	20011030	US 1999-336548	19990619
PRIORITY APPLN. INFO.: US 1999-336548 A 19990619 <--				
AB The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compns. comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compns. For example, a conjugate of insulin, PEG, and oleic acid was prepd. and can be orally administered.				
IT 50-56-6, Oxytocin, biological studies 58-82-2, Bradykinin 69-25-0, Eledoisin 1947-37-1, Tetragastrin 5534-95-2, Pentagastrin 9063-57-4, Taftsin 16679-58-6, Desmopressin 17650-98-5, Caerulein 25126-32-3, Cholecystokinin-8 (swine) 33507-63-0, Substance P 105250-86-0, Ebiratide RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amphiphilic drug-oligomer <b>conjugates</b> with hydrolyzable <b>lipophile</b> components)				
RN 50-56-6 HCAPLUS				
CN Oxytocin (8CI, 9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

RN 58-82-2 HCAPLUS  
 CN Bradykinin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B





RN 69-25-0 HCAPLUS  
 CN Eledoisin (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 1947-37-1 HCAPLUS  
CN 4-7-Cholecystokinin-7 (swine) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 5534-95-2 HCAPLUS  
CN 3-7-Cholecystikinin-7 (swine), 3-[N-[(1,1-dimethylethoxy)carbonyl]-.beta.-alanine]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 9063-57-4 HCAPLUS

CN L-Arginine, L-threonyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 16679-58-6 HCAPLUS

CN Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— NH<sub>2</sub>


— NH—C—NH<sub>2</sub>  
||  
NH

RN 17650-98-5 HCAPLUS


CN Caerulein (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 25126-32-3 HCAPLUS

CN Cholecystokinin-8 (swine) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OSO<sub>3</sub>H


RN 33507-63-0 HCAPLUS  
CN Substance P (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

NH<sub>2</sub>

PAGE 2-A




RN 105250-86-0 HCAPLUS

CN L-Phenylalaninamide, (2S)-2-amino-4-(methylsulfonyl)butanoyl-L-.alpha.-

glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-N.alpha.-(8-aminooctyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



=&gt; d ibib abs hitstr 6

L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2000:383983 HCAPLUS  
 DOCUMENT NUMBER: 133:34431  
 TITLE: Transport system conjugate  
 INVENTOR(S): Imfeld, Dominik; Ludin, Christian; Schreier, Thomas  
 PATENT ASSIGNEE(S): Pentapharm A.-G., Switz.  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: **Patent**  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032235	A1	20000608	WO 1999-CH567	19991126 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1133317	A1	20010919	EP 1999-955629	19991126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002035243	A1	20020321	US 2001-866824	20010529 <--
PRIORITY APPLN. INFO.: CH 1998-2354 A 19981126 <--				
WO 1999-CH567 W 19991126				

OTHER SOURCE(S): MARPAT 133:34431

AB A pharmaceutical and/or cosmetic active agent is conjugated, directly or via a linker, to an amino or carboxyl group on substituent Y of a lipophilic compd. Y(NHCnH2n)rC(O)R [Y = amino acid or di- or tripeptide having .gtoreq.3 reactive NH2 and/or CO2H groups, or a C2-8 triamine; RC(O) = (substituted) C4-24 fatty acyl; n = 2, 3; r = 0, 1], where another amino group on Y is attached to a group C(O)(CH2)mCH(SH)CH2(CHR1)pSH or its cyclic disulfide deriv., to facilitate transmembrane transport of the active agent into fibroblasts, keratinocytes, melanocytes, and Langerhans cells of the skin. Thus, .alpha.-MSH-induced melanin formation in S91 melanocytes was inhibited by treating the cells with a conjugate of tyrosinase-mimicking peptide with the transporter H-Lys(.epsilon.-DL-6,8-dithiooctanamide)-NHCH2CH2NHC(O)(CH2)6CH3. Similarly, conjugates of cell growth modulators can be used to inhibit hyperproliferation of keratinocytes in treatment of psoriasis.

IT 50-56-6, Oxytocin, biological studies 15483-57-5

16679-58-6, Adiuretin 273928-52-2 273928-53-3

273928-54-4 273928-55-5 273928-56-6

273928-57-7 273928-58-8 273928-60-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(lipophilic conjugates; transport system conjugate)

RN 50-56-6 HCAPLUS

CN Oxytocin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

RN 15483-57-5 HCAPLUS

CN L-Glutamic acid, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 16679-58-6 HCAPLUS

CN Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—NH<sub>2</sub>

$$\begin{array}{c} \text{—NH—C—NH}_2 \\ \parallel \\ \text{NH} \end{array}$$

RN 273928-52-2 HCAPLUS

CN L-Aspartic acid, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273928-53-3 HCAPLUS

CN L-Lysine, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 273928-54-4 HCAPLUS

CN L-Cysteine, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-seryl-L-threonyl-L-alanyl-L-leucyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273928-55-5 HCAPLUS

CN L-Aspartic acid, L-alanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 273928-56-6 HCAPLUS

CN L-Glutamic acid, L-alanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 273928-57-7 HCAPLUS


CN L-Cysteine, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 273928-58-8 HCAPLUS


CN L-Cysteine, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-leucyl-L-threonyl-L-alanyl-L-leucyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 273928-60-2 HCAPLUS


CN L-Leucine, L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-tyrosyl-L-histidyl-L-seryl-L-leucyl-L-tyrosyl-L-asparaginyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





||  
O

REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d ibib abs hitstr 7

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:717940 HCAPLUS

DOCUMENT NUMBER: 127:331756

TITLE: Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (vip)

INVENTOR(S): Gozes, Ilana; Fridkin, Matityahu

PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel; Ramot University Authority for Applied Research and Industrial Development Lt; Gozes, Ilana; Fridkin, Matityahu

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740070	A1	19971030	WO 1997-IL129	19970418 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2252458	AA	19971030	CA 1997-2252458	19970418 <--
AU 9725753	A1	19971112	AU 1997-25753	19970418 <--
AU 715036	B2	20000113		
EP 904294	A1	19990331	EP 1997-917393	19970418 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1219938	A	19990616	CN 1997-194970	19970418 <--
JP 2001502294	T2	20010220	JP 1997-537899	19970418 <--
US 6239107	B1	20010529	US 1999-171654	19990429 <--
PRIORITY APPLN. INFO.: IL 1996-118003 A 19960423 <--				
WO 1997-IL129 W 19970418 <--				
OTHER SOURCE(S): MARPAT 127:331756				
AB Novel conjugates of peptides having 3-12 amino acid residues and lipophilic moieties, which may be present at the N- or C- terminal of the peptides, have been prepd. for the treatment of male impotence or neurodegenerative diseases. Thus, peptide conjugate St-Lys-Lys-Tyr-Leu-NH2 (St = stearyl) was prepd. and assayed for neuronal survival (80-110% at 10-3-10-9 M).				
IT 197907-73-6P 197907-75-8P 197907-77-0P				
197907-79-2P 197907-81-6P 197907-82-7P				
197907-84-9P 197907-85-0P 197907-86-1P				
197907-87-2P 197907-88-3P 197907-89-4P				
197907-90-7P 197907-91-8P 197907-92-9P				
197907-93-0P 197907-94-1P 197907-95-2P				
197907-96-3P 197907-97-4P 197907-98-5P				
197907-99-6P 197908-00-2P 197908-01-3P				
197963-42-1DP, fragments				
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP				


(Preparation); USES (Uses)

(conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide)

RN 197907-73-6 HCAPLUS

CN L-Leucinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-75-8 HCAPLUS

CN L-Valinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-77-0 HCAPLUS

CN D-Alaninamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-79-2 HCAPLUS

CN L-Norleucinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 197907-81-6 HCAPLUS

CN L-Leucinamide, N2-(1-oxododecyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 197907-82-7 HCAPLUS

CN L-Leucinamide, N2-(1-oxohexyl)-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-84-9 HCAPLUS

CN L-Leucinamide, N-(1-oxooctadecyl)-L-valyl-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-85-0 HCAPLUS

CN L-Norleucinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-86-1 HCAPLUS

CN L-Aspartamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-87-2. HCAPLUS

CN L-Serinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-88-3 HCAPLUS

CN L-Isoleucinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-89-4 HCAPLUS

CN L-Leucinamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 197907-90-7 HCAPLUS

CN L-Aspartamide, N2-(1-oxooctadecyl)-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 197907-91-8 HCAPLUS

CN L-Aspartamide, N-(1-oxooctadecyl)-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-92-9 HCAPLUS

CN L-Aspartamide, N-(1-oxooctadecyl)-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 197907-93-0 HCAPLUS

CN L-Aspartamide, N-(1-oxooctadecyl)-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—NH<sub>2</sub>

—NH<sub>2</sub>

RN 197907-94-1 HCAPLUS

CN L-Leucinamide, N-(1-oxooctadecyl)-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-95-2 HCAPLUS

CN L-Aspartamide, N2-(1-oxooctadecyl)-L-asparaginyl-L-seryl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 197907-96-3 HCAPLUS

CN L-Aspartamide, N2-(1-oxooctadecyl)-L-asparaginyl-L-seryl-L-isoleucyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 197907-97-4 HCAPLUS


CN L-Aspartamide, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-prolyl-L-prolyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 197907-98-5 HCAPLUS  
 CN L-Aspartamide, N-(1-oxooctadecyl)-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH<sub>2</sub>NH<sub>2</sub>


PAGE 2-A



RN 197907-99-6 HCAPLUS

CN L-.alpha.-Asparagine, N2-(1-oxooctadecyl)-L-lysyl-L-lysyl-L-lysyl-L-


tyrosyl-L-leucyl-, (6.fwdarw.1)-lactam (9CI) (CA INDEX NAME)



RN 197908-00-2 HCAPLUS


CN L-Cysteinamide, N-(1-oxooctadecyl)-L-cysteinyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-, cyclic (1.fwdarw.6)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197908-01-3 HCAPLUS

CN L-Lysinamide, N-(1-oxooctadecyl)-L-cysteinyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-N6-(mercaptoacetyl)-, cyclic (1.fwdarw.6)-thioether (9CI) (CA INDEX NAME)




RN 197963-42-1 HCAPLUS


CN Vasoactive intestinal octacosapeptide (swine), 7-L-tyrosine- (9CI) (CA INDEX NAME).

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-C



PAGE 1-D



PAGE 2-D



=&gt; d ibib abs hitstr 8

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:435277 HCAPLUS

DOCUMENT NUMBER: 125:81300

TITLE: Peptides and their analogs and lipid analog conjugates  
for coupling to surfaces for binding of lipid layers  
and hydrophobic proteins

INVENTOR(S): Naumann, Renate; Jonczyk, Alfred

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 12 pp.

CODEN: GWXXBX

DOCUMENT TYPE: **Patent**

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4444893	A1	19960620	DE 1994-4444893	19941216
WO 9618645	A1	19960620	WO 1995-EP4681	19951129 <--
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9642575	A1	19960703	AU 1996-42575	19951129 <--
EP 800529	A1	19971015	EP 1995-941036	19951129 <--
R: CH, DE, FR, GB, IT, LI, NL, SE				
JP 10510277	T2	19981006	JP 1995-518177	19951129 <--
US 5962638	A	19991005	US 1997-849825	19970613 <--
PRIORITY APPLN. INFO.:			DE 1994-4444893	19941216 <--
			WO 1995-EP4681	19951129 <--

OTHER SOURCE(S): MARPAT 125:81300

AB Pentapeptides and a range of analogs that are suitable for conjugation to surfaces and to lipids to create an environment for the formation of lipid mono- and bi-layers are described and members of the family are synthesized. The lipid layers created using these compds. are useful for the binding of proteins, e.g. in the prepn. of enzyme electrodes. Solid phase synthesis of a no. of peptides and their dicyclohexylcarbodiimide conjugation with alkyl thiols is demonstrated. A no. of analogs were conjugated to cold particles via the alkyl thiol moiety and the resulting layer was then conjugated with dimyristoylphosphatidyl ethanolamine and liposomes contg. the Escherichia coli EF0F1 ATPase were bound to this surface. Surface plasmon resonance showed that the lipid layer was 4 nm thick without the added enzyme and 8.5 nm thick in the presence of the enzyme. Square wave voltammetry showed the proton discharge to be a function of the ATP concn.

IT 178765-98-5P 178765-99-6P 178766-00-2P  
178766-01-3P 178766-02-4P 178766-03-5P  
178766-04-6P


RL: ARU (Analytical role, unclassified); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)  
(synthesis and **conjugation** to gold surfaces of; peptides and their analogs and lipid analog **conjugates** for coupling to surfaces for binding of lipid layers and **hydrophobic** proteins)

RN 178765-98-5 HCAPLUS


CN L-Alanine, N-[N-[N-[N-[N-[N-[1-oxo-3-[(triphenylmethyl)thio]propyl]-L-alanyl]-L-seryl]-L-seryl]-L-alanyl]-L-alanyl]-L-seryl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 178765-99-6 HCAPLUS


CN L-Alanine, N-(3-mercapto-1-oxopropyl)-L-alanyl-L-seryl-L-seryl-L-alanyl-L-alanyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 178766-00-2 HCAPLUS

CN L-Alanine, N-[N-[N-[N-[N-[1-oxo-3-[(triphenylmethyl)thio]propyl]-L-alanyl]-L-alanyl]-L-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CPh<sub>3</sub>

RN 178766-01-3 HCAPLUS

CN L-Alanine, N-[N-[N-[N-[N-(3-mercapto-1-oxopropyl)-L-alanyl]-L-alanyl]-L-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178766-02-4 HCAPLUS

CN L-Alanine, N-[N-[N-[N-[N-[5-(1,2-dithiolan-3-yl)-1-oxopentyl]-L-alanyl]-L-alanyl]-L-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—CO<sub>2</sub>H

RN 178766-03-5 HCAPLUS


CN L-Lysine, N2-[1-[N-[N-[N-[N2-[N-[N-[N-[1-oxo-11-[[1-oxo-3-  
 [(triphenylmethyl)thio]propyl]amino]undecyl]glycyl]glycyl]glycyl]-L-  
 arginyl]glycyl]-L-.alpha.-aspartyl]-L-seryl]-L-prolyl]- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 178766-04-6 HCAPLUS

CN L-Lysine, N2-[1-[N-[N-[N-[N2-[N-[N-[N-[11-[(3-mercapto-1-oxopropyl)amino]-  
 1-oxoundecyl]glycyl]glycyl]glycyl]-L-arginyl]glycyl]-L-.alpha.-aspartyl]-L-  
 seryl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

